Integer (NYSE:ITGR) Upgraded by Bank of America to “Buy”

Integer (NYSE:ITGR) was upgraded by research analysts at Bank of America from a “neutral” rating to a “buy” rating in a report issued on Monday, MarketBeat Ratings reports. The brokerage currently has a $135.00 price target on the medical equipment provider’s stock, up from their prior price target of $105.00. Bank of America‘s price objective suggests a potential upside of 13.15% from the stock’s current price.

ITGR has been the topic of several other reports. KeyCorp upped their target price on Integer from $123.00 to $139.00 and gave the company an “overweight” rating in a research report on Tuesday, April 9th. Benchmark increased their price objective on Integer from $105.00 to $130.00 and gave the company a “buy” rating in a report on Thursday, March 28th. Finally, CL King started coverage on Integer in a report on Thursday, March 14th. They issued a “buy” rating and a $137.00 price objective on the stock. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $120.50.

Integer Trading Up 0.6 %

Shares of NYSE:ITGR opened at $119.31 on Monday. The business’s 50-day moving average is $111.09 and its 200 day moving average is $97.94. Integer has a 1 year low of $69.40 and a 1 year high of $121.53. The firm has a market capitalization of $4.00 billion, a P/E ratio of 44.35, a P/E/G ratio of 1.46 and a beta of 1.10. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.80 and a quick ratio of 1.71.

Integer (NYSE:ITGR) last announced its earnings results on Thursday, February 15th. The medical equipment provider reported $1.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.34 by $0.05. Integer had a return on equity of 10.80% and a net margin of 5.68%. The company had revenue of $413.15 million for the quarter, compared to analyst estimates of $409.04 million. During the same period in the prior year, the company posted $1.11 EPS. The firm’s quarterly revenue was up 10.9% compared to the same quarter last year. On average, research analysts predict that Integer will post 5.28 earnings per share for the current fiscal year.

Institutional Trading of Integer

A number of hedge funds have recently modified their holdings of ITGR. Raymond James & Associates boosted its stake in shares of Integer by 12.6% in the first quarter. Raymond James & Associates now owns 40,898 shares of the medical equipment provider’s stock worth $3,295,000 after buying an additional 4,578 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Integer by 1.3% in the first quarter. Bank of New York Mellon Corp now owns 406,645 shares of the medical equipment provider’s stock worth $32,763,000 after buying an additional 5,256 shares during the last quarter. American Century Companies Inc. boosted its position in Integer by 20.9% during the first quarter. American Century Companies Inc. now owns 5,573 shares of the medical equipment provider’s stock worth $449,000 after purchasing an additional 963 shares in the last quarter. US Bancorp DE boosted its position in Integer by 11.8% during the first quarter. US Bancorp DE now owns 9,970 shares of the medical equipment provider’s stock worth $803,000 after purchasing an additional 1,051 shares in the last quarter. Finally, HighTower Advisors LLC boosted its position in Integer by 2.9% during the first quarter. HighTower Advisors LLC now owns 7,831 shares of the medical equipment provider’s stock worth $632,000 after purchasing an additional 217 shares in the last quarter. Hedge funds and other institutional investors own 99.29% of the company’s stock.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.